Collegium Pharmaceutical, Inc. announced updates to its Board of Directors and the appointment of three new executive leaders. Gino Santini, the Board’s Lead Independent Director, will become Chairman, succeeding Founder and Chairman Michael Heffernan, who will retire from the Board at the Annual General Meeting on May 15, 2025. Board Member Gwen A. Melincoff will also retire.
Dr. Carlos Paya, a physician-scientist with over 30 years of experience in the biopharmaceutical industry, has been nominated to the Board of Directors for shareholder approval at the AGM. These changes reflect the Board’s focus on refreshment and succession planning, following the appointment of Nancy S. Lurker in February 2025.
The company also appointed three new executive leaders: David Dieter as Executive Vice President, General Counsel; Jane Gonnerman as Executive Vice President, Strategy and Corporate Development; and Dean J. Patras as Chief People Officer. These appointments are aimed at strengthening the leadership team as Collegium drives a new phase of growth, focusing on Jornay PM and strategic capital deployment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.